溢多利(300381) - 2022 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2022 was ¥753,881,379.40, a decrease of 13.46% compared to ¥871,145,680.75 in the same period last year[24]. - The net profit attributable to shareholders was ¥15,557,366.99, down 74.26% from ¥60,441,377.69 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was -¥44,140,254.36, a decline of 181.44% compared to ¥54,198,469.66 in the previous year[24]. - The basic earnings per share decreased by 74.29% to ¥0.0317 from ¥0.1233 in the same period last year[24]. - The company's operating revenue decreased by 13.46% compared to the same period last year, primarily due to the sale of the pharmaceutical segment and fluctuations in the agricultural and animal husbandry industry[36]. - The net profit attributable to shareholders decreased by 74.26% year-on-year, influenced by the sale of pharmaceutical assets and rising costs of raw materials and energy[36]. - The company reported a net profit of 9,957,018 yuan for its subsidiary, Changsha Shiwai Technology Co., Ltd[88]. - The company reported a net profit of CNY 28,597,536.82 for the first half of 2022, down from CNY 77,131,610.12 in the same period of 2021[194]. - The company reported a significant increase in cash inflows from investment activities, totaling CNY 1,167,764,227.30, compared to CNY 18,598.00 in the first half of 2021[199]. Cash Flow and Investments - The net cash flow from operating activities increased by 118.51% to ¥259,719,135.99 from ¥118,858,939.19 in the same period last year[24]. - Cash flow from operating activities increased by 118.51% to ¥259,719,135.99, primarily due to reduced cash payments for goods[41]. - The cash and cash equivalents increased by 310.12% to ¥760,648,689.88, largely due to cash received from equity transfers[41]. - The company reported an investment income of ¥132,908,344.57, a dramatic increase of 11,394.49% attributed to the transfer of subsidiary equity[45]. - The company reported a significant transaction involving the sale of equity, contributing a net profit of 1,229 million yuan, which represents approximately 24.58% of the total net profit[82]. - The company reported a total investment of ¥590,993,963.36 for the reporting period, representing a significant increase of 219.98% compared to ¥184,698,360.88 in the same period last year[58]. - The company has ongoing projects with significant investments, including a biological enzyme production facility with an annual capacity of 20,000 tons[60]. Asset Management - Total assets decreased by 30.74% to ¥3,102,946,583.17 from ¥4,479,934,615.27 at the end of the previous year[24]. - The company's total assets as of the reporting date included fixed assets of ¥4,953,438.97 and intangible assets of ¥2,786,289.01, both subject to loan financing[56]. - The company's total assets were CNY 2,916,193,625.42 in the first half of 2022, down from CNY 3,087,246,032.65 in the same period of 2021[193]. - The company's equity decreased to CNY 2,827,906,384.76 from CNY 3,048,007,590.50, reflecting a decline of approximately 7.2%[187]. - The company reported a significant reduction in inventory, which fell to CNY 186,330,216.28 from CNY 992,450,259.82, a decrease of about 81.2%[185]. Business Strategy and Market Focus - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company is investing in multiple projects in biological enzyme preparations and animal nutrition, supported by national policies and market demand, but faces uncertainties due to macroeconomic changes and industry competition[6]. - The company is expanding its product offerings in active natural products and animal nutrition and health, expecting a recovery in profitability as the agricultural sector stabilizes[36]. - The company aims to become a benchmark enterprise in the global enzyme preparation industry and a leading enterprise in functional feed additives in China[38]. - The company plans to focus on the health sector, emphasizing the development of new biological products using modern biotechnology[90]. - The company aims to strengthen its core businesses in biological enzyme preparations, active natural products, and animal husbandry and health[90]. - The company is committed to developing new biological products and expanding its market presence in the health and nutrition sectors[83]. Risk Management - The company faces short-term performance fluctuation risks due to the sale of its pharmaceutical business assets, which accounted for 48.83% of revenue in 2021[5]. - The company reported a significant impact on actual profits due to macroeconomic slowdown, increased industry competition, and rising labor costs[72]. - The company has established a comprehensive internal control system to ensure the safety of its overseas assets, which include Victory Enzymes GmbH in Germany and a subsidiary in Macau[53]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[105]. Corporate Governance and Compliance - The company has committed to not engaging in any competitive activities with its subsidiaries, ensuring no conflicts of interest arise[110]. - The company guarantees that there are no significant violations or penalties related to environmental, safety, or quality regulations since its establishment[112]. - The company has pledged to disclose any potential conflicts of interest and ensure fair market practices in related transactions[111]. - The company has confirmed that it will not provide technical information or trade secrets to competitors[110]. - The company has established a long-term commitment to fulfill its obligations and ensure compliance with all relevant laws and regulations[111]. Shareholder Information - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., holds 30.97% of the shares, totaling 141,615,094 shares[158]. - The company has a total of 19,095 shareholders at the end of the reporting period[156]. - The company approved a share repurchase plan on May 17, 2022, with a total fund of no less than RMB 100 million and no more than RMB 200 million, at a maximum price of RMB 12.50 per share[153]. - As of June 30, 2022, the company repurchased a total of 5,135,800 shares, accounting for 1.05% of the total share capital, with a total transaction amount of RMB 49,870,166.62[154].